Divine Skin Adds Keith Markey, Ph.D. to Its Board of Directors
Dr. Markey is a Well Respected Research Analyst
MIAMI BEACH, Fla., July 9, 2012 /PRNewswire/ — Divine Skin Inc., (DSKX) a leading developer and formulator of personal care products, today announced it has added Dr. Keith Markey to its Board of Directors.
Dr. Markey has been a research analyst for Griffin Securities for the past 5 years and has more than 25 years of experience in the financial services industry. His focus has been primarily on healthcare, biotech and medical device companies. Previously, Dr. Markey held various managerial positions in the Value Line Research Department, supporting the Value Line Investment Survey with original research and by selecting stocks for coverage. He began his career as a biochemist, working in the fields of endocrinology and neuroscience. His research, which resulted in more than 30 publications, contributed to the understanding of regulatory biochemistry and stem cell plasticity. Keith has lectured on scientific and financial subjects and is a member of the Licensing Executive Society and the National Association of Science Writers. He earned a Ph.D. in Neurochemistry from the University of Connecticut and an M.B.A. in Finance from the Leonard N. Stern School of Business at New York University.
Divine Skin’s CEO Daniel Khesin stated, “We are extremely pleased to have someone as experienced and knowledgeable as Dr. Markey joining our Board of Directors. We welcome Dr. Markey to the Divine Skin team.”
About Divine Skin
Divine Skin Inc. leads in the development of biotechnology for topical, nutritional, and pharmaceutical therapies. It markets worldwide through online and specialty retailers, cosmetics wholesalers, salons, and medical offices. The fast-growing company went public in 2009.
DS Laboratories, its flagship brand, offers high-performance topical solutions to restore growth and radiance to hair, suppress dandruff and unwanted hair, control acne, improve hygiene, and reduce cellulite and wrinkles. Bioavailability is enhanced through Nanosome encapsulation (www.DSLaboratories.com).
The Sigma Skin brand sells through upscale retailers like Neiman Marcus in the United States and Harvey Nichols in the United Kingdom. The topical products address hair loss and other signs of aging. (www.SigmaSkin.com).
Polaris Research Laboratories makes high-potency minoxidil-based hair-growth formulas (PolarisResearchLabs.com).
The Pure Guild offers purity with performance: Botanical compounds proven effective in clinical trials are extracted without industrial solvents or damaging heat and are sold through premium retailers (ThePureGuild.com).
Forward-Looking Statements:
Except for statements of historical fact, the matters discussed in this press release are forward-looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “future,” “plan” or “planned,” “expects,” or “projected.” These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company’s control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing and marketing products, intense competition and additional risks factors as discussed in reports filed by the company with the Securities and Exchange Commission, which are available at http://www.sec.gov.
Divine Skin Adds Keith Markey, Ph.D. to Its Board of Directors
Dr. Markey is a Well Respected Research Analyst
MIAMI BEACH, Fla., July 9, 2012 /PRNewswire/ — Divine Skin Inc., (DSKX) a leading developer and formulator of personal care products, today announced it has added Dr. Keith Markey to its Board of Directors.
Dr. Markey has been a research analyst for Griffin Securities for the past 5 years and has more than 25 years of experience in the financial services industry. His focus has been primarily on healthcare, biotech and medical device companies. Previously, Dr. Markey held various managerial positions in the Value Line Research Department, supporting the Value Line Investment Survey with original research and by selecting stocks for coverage. He began his career as a biochemist, working in the fields of endocrinology and neuroscience. His research, which resulted in more than 30 publications, contributed to the understanding of regulatory biochemistry and stem cell plasticity. Keith has lectured on scientific and financial subjects and is a member of the Licensing Executive Society and the National Association of Science Writers. He earned a Ph.D. in Neurochemistry from the University of Connecticut and an M.B.A. in Finance from the Leonard N. Stern School of Business at New York University.
Divine Skin’s CEO Daniel Khesin stated, “We are extremely pleased to have someone as experienced and knowledgeable as Dr. Markey joining our Board of Directors. We welcome Dr. Markey to the Divine Skin team.”
About Divine Skin
Divine Skin Inc. leads in the development of biotechnology for topical, nutritional, and pharmaceutical therapies. It markets worldwide through online and specialty retailers, cosmetics wholesalers, salons, and medical offices. The fast-growing company went public in 2009.
DS Laboratories, its flagship brand, offers high-performance topical solutions to restore growth and radiance to hair, suppress dandruff and unwanted hair, control acne, improve hygiene, and reduce cellulite and wrinkles. Bioavailability is enhanced through Nanosome encapsulation (www.DSLaboratories.com).
The Sigma Skin brand sells through upscale retailers like Neiman Marcus in the United States and Harvey Nichols in the United Kingdom. The topical products address hair loss and other signs of aging. (www.SigmaSkin.com).
Polaris Research Laboratories makes high-potency minoxidil-based hair-growth formulas (PolarisResearchLabs.com).
The Pure Guild offers purity with performance: Botanical compounds proven effective in clinical trials are extracted without industrial solvents or damaging heat and are sold through premium retailers (ThePureGuild.com).
Forward-Looking Statements:
Except for statements of historical fact, the matters discussed in this press release are forward-looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “future,” “plan” or “planned,” “expects,” or “projected.” These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company’s control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing and marketing products, intense competition and additional risks factors as discussed in reports filed by the company with the Securities and Exchange Commission, which are available at http://www.sec.gov.